Recent Updates — USNA

On September 30, 2026, USANA Health Sciences entered into a First Amendment to its Third Amended and Restated Credit Agreement with Bank of America. The amendment raises the annual general asset sale basket limit from $500,000 to $2,500,000 and permits the sale of real property in Sydney, Australia. It also establishes a minimum Consolidated EBITDA covenant of $100 million for trailing four-fiscal-quarter periods beginning with the quarter ending October 3, 2026, reducing this threshold to $70 million if revolving exposure is $50 million or less. The company reaffirmed its obligations and confirmed no defaults exist under the loan documents. USANA Health Sciences manufactures and sells nutritional supplements, skin care products, and personal care items.

USANA Health Sciences reported a net loss of $21.4 million for the second quarter ended July 4, 2026, driven by a $29.1 million preliminary non-cash goodwill impairment charge at its Hiya subsidiary and lower-than-expected performance from ventures Hiya and Rise Wellness. Consolidated net sales declined 5% year-over-year to $223 million, with Core Nutritional sales down 4% to $192 million while Hiya sales fell 17% to $28 million. The company updated its full-year fiscal 2026 outlook, lowering consolidated net sales guidance to $910 million and forecasting a net loss of $11 million compared to previous expectations of earnings between $20 million and $27 million. USANA operates in the health and wellness industry, developing and manufacturing nutritional supplements, functional foods, and personal care products sold through direct selling and retail channels.